Remove Diagnostic Remove Image Interpretation Remove Medical Imaging Remove Radiopharmaceuticals
article thumbnail

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

Chief Executive Officer of Blue Earth Diagnostics. Blue Earth Diagnostics will also host an Industry-Expert Theater event, ‘POSLUMA: Precision PET Imaging that is Truly Revealing’.” PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging Presenter: Phillip H. Gauden , D.Phil.,

article thumbnail

Meet the Minnies 2024 semifinal candidates

AuntMinnie

The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. Horowitz, et al, Medical Hypotheses , October 13, 2023. Central Vein Sign in Multiple Sclerosis: A Comparison Study of the Diagnostic Performance of 3T versus 7T MRI.

article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. The demonstrated performance of PSMA-PET imaging fits an important unmet need, given that conventional imaging techniques are limited in the information they provide. “We Chief Executive Officer of Blue Earth Diagnostics.